Abbreviations used in this paper: GDP, guanosine diphosphate; TRIM, tripartite motif.

Arf family history: Arfs, Arls, SARs, and other members
=======================================================

Arfs.
-----

Arf was first discovered, purified, and functionally defined as the protein cofactor required for cholera toxin--catalyzed ADP ribosylation of the stimulatory regulatory subunit (Gs) of adenylyl cyclase ([@bib10]; [@bib14]) and, shortly thereafter, was shown to be a GTP-binding protein ([@bib15]). Use of the acronym Arf is currently preferred to ADP ribosylation factor, as only Arf1--6 shares the cofactor activity for cholera toxin and because ADP ribosylation does not appear to be involved in any aspect of the normal cellular actions of any member of the family. The use of all capital letters (e.g., ARF1) refers specifically to the human gene or protein, whereas when only the first letter is capitalized (e.g., Arf1), it may refer to the protein from more than one species, an activity, or a group of proteins. Since their discovery, they have been found to be ubiquitous regulators of membrane traffic and phospholipid metabolism in eukaryotic cells (for reviews and discussion of Arf actions see [@bib27]; [@bib6]; Kahn, 2004). Arfs are soluble proteins that translocate onto membranes in concert with their activation, or GTP binding. The biological actions of Arfs are thought to occur on membranes and to result from their specific interactions with a large number of effectors that include coat complexes (COPI, AP-1, and AP-3), adaptor proteins (GGA1-3 and MINT1-3/X11α-γ/APBA1-3), lipid-modifying enzymes (PLD1, phosphatidylinositol (4,5)-kinase, and phosphatidylinositol (4)-kinase), and others. Arf proteins are activated by guanosine diphosphate (GDP) to GTP exchange, which is stimulated by the Sec7 domain of Arf guanine nucleotide exchange factors, and their activity is terminated upon the hydrolysis of GTP, which is stimulated by interaction with an Arf GTPase-activating protein.

Cloning and sequencing of the first Arf family member ([@bib34]) led directly to the realization that Arfs are closely related to both the Ras and heterotrimeric G protein α subunit families of GTPases, and all are thought to have arisen from a common ancestor. The very high degree of conservation of Arf sequences in eukaryotes (74% between human and yeast) was also noted early on and has allowed the ready identification of orthologues in every examined eukaryote, including *Giardia lamblia*, which lack Ras and G protein α subunits ([@bib25]).

Cloning by low stringency hybridization and chance led to the identification of additional members of the Arf family in a wide array of eukaryotic species. The number of mammalian Arfs grew to six by 1992 ([@bib36]) and were named in their order of discovery ([@bib30]; [@bib4]; [@bib16]; [@bib19]). The first confusion in the nomenclature was that the current human ARF4 was originally published with the name ARF2 ([@bib16]). In fact, humans appear to have lost the ARF2 orthologue, which is present in other mammals (including rats, mice, and cows). The combination of protein sequence comparisons and intron/exon boundaries of Arf genes led to further classification of the six mammalian Arfs into classes: class I (ARF1--3 are \>96% identical), class II (ARF4 and ARF5 are 90% identical to each other and 80% identical to the other Arfs), and class III (ARF6 is 64--69% identical to the other Arfs). Phylogenetic analyses support the conclusion that the three classes of Arf diverged early, as flies and worms have single representatives of each of the three classes, and the number of genes/proteins in class I and II were later expanded in vertebrates.

Arls.
-----

The initial criteria for naming new Arfs were functional, and only those proteins that could (1) serve as cofactors for cholera toxin, (2) rescue the lethal *arf1* ^−^ *arf2* ^−^ deletion in *Saccharomyces cerevisiae*, and (3) directly activate PLD were given the name Arf. Thus, with the chance cloning of an essential gene in *Drosophila melanogaster* that encoded a protein closely related to the Arfs (50--60% identity) but lacking in these activities, it was named *arflike* ([@bib35]). When orthologues were found in several other species, the name was changed to Arf-like 1 (*ARL1*) in those species ([@bib17]; [@bib5]; [@bib23]). Note that although the name Arf still denotes a protein with one or more specific functions or activities, the term Arl does not. The term Arl indicates only that the protein is structurally related to Arfs. Thus, the Arls are not a coherent group either functionally or phylogenetically.

PCR amplification with degenerate oligonucleotide primers ([@bib9]; [@bib31]) revealed the existence of a large number of mammalian cDNAs encoding closely related proteins. The next to be cloned and sequenced were *ARL2* ([@bib9]), *ARL3* ([@bib7]), *ARL4* ([@bib31]), and *ARL5* ([@bib5]). Each of the encoded proteins has a glycine at position 2, the site of *N*-myristoylation in all Arf proteins. Note that although ARL2 and ARL3 have the NH~2~-terminal glycine, they appear not to be substrates for *N*-myristoyltransferases.

Around this time, a protein with similar percent identities to the Arf and Arls was found, but it lacked the NH~2~-terminal glycine, was membrane associated, and displayed distinctive nucleotide handling properties ([@bib32]). Thus, it was given the name Arf-related protein 1 (*ARFRP1*) to distinguish it from the Arls and Arfs. We realize today that this was unfortunate, as several of the more recently identified Arls also have functions and biochemical properties that are quite divergent from Arfs.

SARs.
-----

SAR1 was among the earliest members of the Arf family sequenced, and it came out of genetic screens in the yeast *S. cerevisiae* as a suppressor of sec12(ts) ([@bib26]). Its name is derived from its identification as a secretion-associated and Ras-related protein. Cloning of the mammalian orthologues revealed the presence of two closely related (90% identity) proteins/genes ([@bib18]). With \<30% identity to Arfs or Arls, the SAR proteins are only slightly closer in sequence to Arfs than to other families of GTPases, but they also share considerable functional relatedness to Arfs in that they act through the recruitment of coat proteins or complexes to initiate vesicle budding. SARs lack the other aforementioned Arf activities.

Additional domains.
-------------------

An interesting variation is found in ARD1/tripartite motif 23 (TRIM23), a 64-kD protein that possesses a ∼20-kD domain at its COOH terminus with 60% identity to Arfs ([@bib24]). Originally named based on the presence of the Arf domain, ARD1 is also a member of the TRIM family, from which it obtained its current name, TRIM23. A large extension is also seen in ARL13B, a protein of 428 residues that contains an Arl domain at its NH~2~ terminus ([@bib8]; [@bib11]). Although the NH~2~-terminal portion of TRIM23 may possess GTPase-activating protein activity toward its own Arf domain ([@bib38]) and E3 ubiquitin ligase activity ([@bib37]), the COOH-terminal portion of ARL13B has no defined domains or functions to date.

Defining the Arf family
=======================

As the discussion above suggests, there are no shared functions or activities that justify grouping Arf, Arl, and SAR proteins into a family with a common nomenclature. Similarities in protein sequences within the Arf family were first identified by alignment and phylogenetic analyses and were shown to provide distinct signatures that allowed differentiation from Ras, G protein α subunits, and other GTPases. These include an NH~2~-terminal extension, a glycine acceptor for myristate at position 2, an aspartate at position 26 (in contrast to the glycine 12 of Ras that carries oncogenic potential), and other residues that are very highly conserved within the family. These early observations were put on more solid functional footing when they were found to map to unique elements in their three-dimensional structures, which allow for the GDP/GTP switch to be coupled with interaction signals opposite to the nucleotide-binding site (for review see [@bib29]). The prominent feature of this unique nucleotide switch is a nonconventional GDP-bound form in which the two β strands that connect the nucleotide-sensitive switch 1 and 2 regions (also called the interswitch) are retracted in the protein core and must undergo a two-residue shift to reach the active conformation ([Fig. 1](#fig1){ref-type="fig"}). However, the interswitch cannot do so unless the NH~2~-terminal helical extension, which caps the interswitch and locks it in the retracted conformation, has been displaced. In the case of ARF1, biochemical studies have established that this requires the interaction of the NH~2~ terminus with membranes, thus allowing the nucleotide-binding site to detect and respond to remote protein--membrane interactions ([@bib1]). Like Arf proteins, each Sar has an NH~2~-terminal amphipathic helix that functions as a structural GDP/GTP switch to anchor the GTP-bound form to membranes of the endoplasmic reticulum ([@bib12]; [@bib3]). Furthermore, membrane insertion of this NH~2~-terminal helix was recently shown to initiate membrane bending at the early stages of COPII coat assembly and to be subsequently required for the completion of COPII vesicle fission ([@bib20]).

![**The structural "air de famille."** In Arfs, Arls, and SAR proteins, the interswitch toggles from an unusual retracted conformation in the GDP-bound form that is fastened by the NH~2~-terminal helix to an exposed conformation in the GTP-bound form that is stabilized by the W/GG/R signature (shown here for ARF6-GDP and ARF6-GTP). This large conformational change, which involves a two-residue β-strand register shift in the core of the G domain, allows the nucleotide-binding site to detect remote interactions taking place at the NH~2~ terminus (reproduced from [@bib28] with permission).](jcb1720645f01){#fig1}

Structural analysis of ARF1 and ARF6 GDP/GTP cycles and their comparison with those of small GTP-binding proteins whose interswitch does not toggle identified three structural determinants for this movement: a helical NH~2~-terminal extension that fastens the retracted, GDP-bound interswitch; a shorter interswitch that can retract completely; and a sequence signature (wDvGGqXXXRxxW) that provides both flexibility for the movement (GG) and hydrogen bonds for stabilization of the active conformation (R/W). These characteristics are present in all Arf and most Arl sequences, which, therefore, are predicted to have the ability to undergo the interswitch toggle to detect interactions opposite to the nucleotide-binding site, whatever their nature, and propagate them to this site ([@bib29]).

These structural criteria for unifying Arf and Arl proteins as a family have since been supported by various structures of GDP-bound Arf and Arl proteins (Table S1, available at <http://www.jcb.org/cgi/content/full/jcb.200512057/DC1>). It should be noted, however, that one subgroup, ARL4, has a long interswitch that may have lost the ability to toggle, whereas structures of NH~2~-terminally truncated ARL8A and ARL8B bound to GDP have a GTP-like conformation. This suggests that truncation of the NH~2~ terminus is sufficient in this family to destabilize the retracted interswitch or that these proteins have lost their ability to undergo the interswitch toggle. Recent work on ARL3 suggests that proteins interacting with the NH~2~ terminus could also work as the displacing factor as an alternative to membranes ([@bib2]; [@bib33]).

Arf family nomenclature
=======================

[Table I](#tbl1){ref-type="table"} contains information on proposed and previous names as well as other information on the human ARF family members. EST and genomic sequencing resulted in the identification of subsequent Arf-like proteins, and these proteins/genes were often misnamed or named multiple times by different research groups. Some of these names suggest relationships that are misleading, and some are called Arfs despite (presumably) lacking any Arf activities. In many cases, no functional data are yet available for the most recently identified Arf family members. One protein has been referred to by four different names, and some proteins/genes were named by curators of databases responding to specific requests in a manner that disagreed with common usage by researchers in the field. The confusion is magnified when species differences are considered (e.g., yeast Arl3 is the orthologue of ARFRP1).

###### 

**The Arf family GTPases: summary of names, identifiers, and NH~2~-terminal sequences**

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Accepted\                                 Proposed new names                Previous\                                 Former\    Other names\             Accession number\        Length\                                NH~2~-terminal\   Gene\    Human\
  symbols                                                                     HGNC\                                     common\    or information           (protein)                (aa)                                   sequence          locus\   locus
                                                                              symbol                                    name                                                                                                                  ID       
  ----------------------------------------- --------------------------------- ----------------------------------------- ---------- ------------------------ ------------------------ -------------------------------------- ----------------- -------- --------------
  ARF1                                                                        ARF1                                      ARF1                                [NP_001649](NP_001649)   181                                    MGNIFANLFKGL      375      1q42

  ARF3                                                                        ARF3                                      ARF3                                [NP_001650](NP_001650)   181                                    MGNIFGNLLKSL      377      12q13

  ARF4                                                                        ARF4                                      ARF4                                [NP_001651](NP_001651)   180                                    MGLTISSLFSRL      378      3p21.2-p21.1

  ARF5                                                                        ARF5                                      ARF5                                [NP_001653](NP_001653)   180                                    MGLTVSALFSRI      381      7q31.3

  ARF6                                                                        ARF6                                      ARF6                                [NP_001654](NP_001654)   175                                    MGKVLSKIFGNK      382      14q21.3

  ARL1                                                                        ARL1                                      ARL1       ARFL1                    [NP_001168](NP_001168)   181                                    MGGFFSSIFSSL      400      7q13

  ARL2                                                                        ARL2                                      ARL2       ARFL2                    [NP_001658](NP_001658)   184                                    MGLLTILKKMKQ      402      11q13

  ARL3                                                                        ARL3                                      ARL3       ARFL3                    [NP_004302](NP_004302)   182                                    MGLLSILRKLKS      403      10q23.3

  ARL4A[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 4A    ARL4[c](#tblfn3){ref-type="table-fn"}     ARL4                                [NP_005729](NP_005729)   200                                    MGNGLSDQTSIL      10124    7p21-p15.3

  ARL4C[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 4C    ARL7[c](#tblfn3){ref-type="table-fn"}     ARL7       LAK                      [NP_005728](NP_005728)   192                                    MGNISSNISAFQ      10123    2q37.1

  ARL4D[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 4D    ARF4L[c](#tblfn3){ref-type="table-fn"}    ARL9       ARL6/ARF4L/\             [NP_001652](NP_001652)   201                                    MGNHLTEMAPTA      379      17q12-q21
                                                                                                                                   ARL5/ARL4L                                                                                                          

  ARL5A[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 5A    ARL5[c](#tblfn3){ref-type="table-fn"}     ARL5                                [NP_036229](NP_036229)   179                                    MGILFTRIWRLF      26225    2q23.3

  ARL5B[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 5B    ARL8[c](#tblfn3){ref-type="table-fn"}     ARL5B      ARL8/similar to\         [NP_848930](NP_848930)   179                                    MGLIFAKLWSLF      221079   10p12.31
                                                                                                                                   ARL5/ARL5-like                                                                                                      

  ARL5C[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 5C    ARL12[c](#tblfn3){ref-type="table-fn"}    ARL12                               [XP_372668](XP_372668)   179[a](#tblfn1){ref-type="table-fn"}   MGQLIAKLMSIF      390790   17q12

  ARL6                                                                        ARL6                                      ARL6       BBS3                     [NP_115522](NP_115522)   186                                    MGLLDRLSVLLG      84100    3q11.2

  ARL8A[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 8A    ARL10B[c](#tblfn3){ref-type="table-fn"}   ARL8A      ARL10B/GIE2              [NP_620150](NP_620150)   186                                    MIALFNKLLDWF      127829   1q32.1

  ARL8B[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 8B    ARL10C[c](#tblfn3){ref-type="table-fn"}   ARL8B      ARL10C/GIE1              [NP_060654](NP_060654)   186                                    MLALISRLLDWF      55207    3p26.1

  ARL9                                                                        ARL9                                                                          [NP_996802](NP_996802)   123/\                                  MEFLEIGGSK/\      132946   4q12
                                                                                                                                                                                     265[a](#tblfn1){ref-type="table-fn"}   MERGKVKKKE                 

  ARL10[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 10    ARL10A[c](#tblfn3){ref-type="table-fn"}   ARL10A                              [NP_775935](NP_775935)   244                                    MAPRPLGPLVLA      285598   5q35.2

  ARL11                                                                       ARL11                                     ARL11      ARLTS1                   [NP_612459](NP_612459)   196                                    MGSVNSRGHKAE      115761   13q14.2

  ARL13A[b](#tblfn2){ref-type="table-fn"}   ADP ribosylation factorlike 13A   ARL13[c](#tblfn3){ref-type="table-fn"}               dJ341D10.2               NP_001013008             297                                    MFRLLSSCCSCL      392509   Xq22.1

  ARL13B[b](#tblfn2){ref-type="table-fn"}   ADP ribosylation factorlike 13B   ARL2L1[c](#tblfn3){ref-type="table-fn"}              DKFZp761H079             [NP_878899](NP_878899)   428                                    MFSLMASCCGWF      200894   3q11.2

  ARL14[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 14    ARF7[c](#tblfn3){ref-type="table-fn"}     ARL10      ARF7                     [NP_079323](NP_079323)   192                                    MGSLGSKNPQTK      80117    3q25.33

  ARL15[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 15    ARFRP2[c](#tblfn3){ref-type="table-fn"}              [FLJ20051](FLJ20051)     [NP_061960](NP_061960)   204                                    MSDLRITEAFLY      54622    5p15.2

  ARL16[b](#tblfn2){ref-type="table-fn"}    ADP ribosylation factorlike 16                                                         [LOC339231](LOC339231)   [XP_290777](XP_290777)   173[a](#tblfn1){ref-type="table-fn"}   MCLLLGATGVGK      339231   17q25.3

  ARFRP1                                                                      ARFRP1                                    ARFRP1     Arp, Arp1                [NP_003215](NP_003215)   201                                    MYTLLSGLYKYM      10139    20q13.3

  SAR1A[b](#tblfn2){ref-type="table-fn"}                                      SARA1[c](#tblfn3){ref-type="table-fn"}    SAR1A      HsSara1                  [NP_064535](NP_064535)   198                                    MSFIFEWIYNGF      56681    10q22.1

  SAR1B[b](#tblfn2){ref-type="table-fn"}                                      SARA2[c](#tblfn3){ref-type="table-fn"}    SAR1B      HsSara2                  [NP_057187](NP_057187)   198                                    MSFIFDWIYSGF      51128    5q31.1

  TRIM23                                                                      TRIM23                                    ARD1 (α)   ARFD1, RNF46             [NP_001647](NP_001647)   574                                    MATLWNKLGAG       373      5q12.3
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Because of previous usage and to avoid confusion, the new assignments result in there being no gene/protein named ARL7 or ARL12. See Table S2 for a list of earlier names and references in which earlier names were used (available at <http://www.jcb.org/cgi/content/full/jcb.200512057/DC1>).

The sequence currently in the database is predicted to be incorrect, and our corrected information was used herein.

New names approved by the HGNC.

Previous names that were recently changed.

The need for a generally agreed upon nomenclature for the ARF family has become acute as a result of increasing confusion and interest in their study. It is not possible today to propose a completely consistent nomenclature, as there are simply too many studies with some of the earlier discovered proteins (e.g., ARFRP1 should be an ARL).

The nomenclature developed and described in this article builds on previous efforts to describe phylogenetic relationships and bring consistency to nomenclature ([@bib29]; [@bib21]; [@bib22]). It is the result of many discussions between researchers in the field and with the HUGO Genome Nomenclature Committee (HGNC) and has been widely circulated to Arf family researchers. We describe the presence in the human proteome of 29 members of the Arf family and a system for naming newly identified proteins in human or other species. The use of letter suffixes is reserved for those groups of proteins within the family that share higher percent identities and are, therefore, likely to share some level of functional redundancy. One exception to this is the ARL13A and ARL13B proteins, which have been given a common number based upon phylogenetic evidence. The consensus nomenclature for the Arf family is shown in [Table I](#tbl1){ref-type="table"} along with previous names and unique gene/protein identifying information. Note that in three cases (*ARL5C*, *ARL9*, and *ARL16*), the intron/exon boundary predictions in the database are thought to be incorrect (based upon comparisons with sequences in other species), resulting in differences in the predicted protein sequences. In these cases, we use our corrected sequences for comparisons and provide the predicted protein sequences of the human proteins (see supplemental material, available at <http://www.jcb.org/cgi/content/full/jcb.200512057/DC1>). In addition, there is one case (*ARL9*) in which it appears that alternative splicing yields two different proteins, one of which is truncated and predicted to be unable to bind nucleotides, so both are provided in the supplemental protein sequence material.

We also identify several gene sequences that have questionable EST/mRNA support and are likely pseudogenes derived from members of the Arf family. These genes, which are annotated by the HGNC, are therefore not included as Arf family members and are listed, along with their identifiers, in [Table II](#tbl2){ref-type="table"}. It is expected that additional pseudogenes will be found and added to this list over time. We also note some uncertainty as to whether ARL5C in [Table I](#tbl1){ref-type="table"} is a transcribed gene, as it may lack part of the consensus GTP-binding signature depending on which predicted protein sequence is used.

###### 

**Pseudogenes of the Arf family in the human genome**

  ------------------------------------------------------------------------------------------------------------------------------------
  New\     New name                                             Other names/\   Chromosome\   Accession\                 Gene locus\
  symbol                                                        information     location      number                     ID
  -------- ---------------------------------------------------- --------------- ------------- -------------------------- -------------
  ARF1P1   ADP ribosylation factor 1 pseudogene 1                               7q21.3        [XM_498225](XM_498225)     442334

  ARF1P2   ADP ribosylation factor 1 pseudogene 2               ARL17A          17q21.31      [NM_016632](NM_016632).1   51326

  ARF4P    ADP ribosylation factor 4 pseudogene                                 9q34          [NG_001075](NG_001075)     380

  ARF4P2   ADP ribosylation factor 4 pseudogene 2                               20q13.33      [NG_001031](NG_001031)     170485

  ARF4P3   ADP ribosylation factor 4 pseudogene 3                               13q32.3       [XM_372496](XM_372496)     390423

  ARL4P    ADP ribosylation factorlike 4 pseudogene             ARL4B           10q21.2       [XM_370560](XM_370560)     387684

  ARL4P2   ADP ribosylation factorlike 4 pseudogene 2           ARL4B           4p14          [NG_005394](NG_005394)     152709

  SAR1P1   SAR1 gene homologue (*S. cerevisiae*) pseudogene 1   SARAP           6p21          [AL035402](AL035402)       387048

  SAR1P2   SAR1 gene homologue (*S. cerevisiae*) pseudogene 2   SARA1P          10q26.2       [AC026226](AC026226)       641312

  SAR1P3   SAR1 gene homologue (*S. cerevisiae*) pseudogene 3                   4q27          [XP_293671](XP_293671)     344988
  ------------------------------------------------------------------------------------------------------------------------------------

This is a list of the HGNC-recognized pseudogenes from the Arf family along with their locations in the genome, accession numbers, and gene identifiers.

Finally, we note that although the large majority of Arf family members appear to have very broad and perhaps ubiquitous tissue expression patterns, a few are far more restricted in their expression. Thus, it is expected that further additions and perhaps even deletions will be needed to keep the nomenclature of this family current and as consistent as possible. To ensure that new family members are assigned unique symbols, we strongly encourage authors to consult the HGNC before publishing any new names for members of this gene/protein family. This is a confidential service provided by the HGNC that will help prevent future confusion from arising. We also suggest that curators and researchers focusing on other organisms use the information provided in this article as much as possible to simplify and clarify the nomenclature across species.

Other researchers supporting the use of this nomenclature include: Bruno Antonny, Bill Balch, Vytas Bankaitis, Gary Bokoch, Juan Bonifacino, Chris Burd, Jim Casanova, Tamara Caspary, Dany Cassel, Rick Cerione, Pierre Chardin, Philippe Chavrier, Shamshad Cockcroft, Peter Cullen, Ivan de Curtis, Maria Antonella De Matteis, Julie Donaldson, Cryslin D\'Souza-Schorey, John Exton, Victor Faundez, Jim Goldenring, Jean Gruenberg, Alan Hall, Fuchu He, Wangjin Hong, Victor Hsu, Mary Hunzicker-Dunn, Trevor Jackson, Cathy Jackson, Hans Joost, Toshi Katada, Fang-jen Lee, Michel Leroux, Jennifer Lippincott-Schwartz, John Logsdon, Alberto Luini, Vivek Malhotra, Ed Manser, Tobias Meyer, Paul Melancon, Joel Moss, Aki Nakano, Kazu Nakayama, Tommy Nilsson, Susanne Pfeffer, Richard Premont, Paul Randazzo, Anne Ridley, Scotty Robinson, Anne Rosenwald, Craig Roy, Hisataka Sabe, Randy Schekman, Nava Segev, Val Sheffield, Phil Stahl, Elizabeth Sztul, Chris Turner, Anne Theibert, Martha Vaughan, Kanamarlapudi Venkateswarlu, Fred Wittinghofer, Keqiang Ye, and Marino Zerial.
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